In a single centre over two years, four children (7 to 10 years old) with upper limb osteosarcoma underwent chemotherapy followed by forequarter amputation. All patients had preoperative pain and were treated with gabapentin. Nerve sheath catheters were placed in the brachial plexus intraoperatively and left in situ for five to 14 days. After surgery, all patients received local anaesthetic infused via nerve sheath catheters as part of a multimodal analgesia technique. Three of the four patients were successfully treated as outpatients with the nerve sheath catheters in situ. All four children experienced phantom limb pain; however, it did not persist beyond four weeks in any patient.
1
. Limb salvage procedures have replaced amputation as the primary treatment option, but amputation remains necessary in approximately 10% of patients 1 . Forequarter amputation (FQA) has been used for curative resection of locally advanced, high-grade tumours involving the shoulder girdle region and for palliation of patients with locally advanced, unresectable metastatic carcinoma of the region 2 , as it may provide useful pain relief and improve quality of life 3 . At St. Jude Children's Research Hospital we have experience in the direct placement of nerve sheath catheters in the brachial plexus during FQA. Continuous infusion of local anaesthetic through nerve sheath catheters provides excellent postoperative analgesia 4 and in a study of amputation for oncologic indications, long-term follow-up showed that the incidence of phantom limb pain (PLP) in adult patients receiving continuous nerve sheath catheter infusion was lower than that in historical controls 5 . Phantom limb pain is the phenomenon of pain in an absent body part 6 . In the paediatric setting, 48 to 90% of patients may suffer PLP [6] [7] [8] . The incidence of PLP has been reported to be higher in patients requiring proximal versus distal amputations 9 . This case series reports four paediatric patients who underwent FQA for upper limb osteosarcoma with intraoperative placement of nerve sheath catheters. Its purpose is to describe the technique and the outcome in terms of postoperative analgesia and the incidence of PLP. Institutional Review Board approval was obtained to present the information as a case series (Approval No. NR12-117). As no family members were contactable to provide consent to publication, the patients have been further deidentified by modifying non-essential details.
MATERIALS AND METHODS

Nerve sheath catheter placement
Our technique of FQA combines the anterior and posterior approach in which all of the relevant muscles and clavicle are divided first and then the nerves and subclavian vessels are severed. The omohyoid muscle is transected using a posterior approach and the brachial plexus is exposed. The nerve trunks are ligated and divided at the level of the scalenus anterior and medius at the base of the neck. The epineurium of each of the three trunks is exposed and a 20-gauge polyamide catheter (Arrow ® , Teleflex Medical, Reading, PA, USA) is threaded between the epineurium and each severed trunk under direct observation and as far as can easily be introduced (3 to 5 cm proximal to the transection level). The three catheters are then secured with a resorbable suture to the soft tissue surrounding the nerves and exited at a site distant from the wound closure ( Figure 1) .
Before wound closure, the catheters are connected to a three-stopcock manifold system and injected with a bolus of local anaesthetic solution. The concentrations and volumes used in this series are listed in Table 1 .
Drug management
At the conclusion of surgery, patients are extubated and transferred to the post-anaesthetic care unit. Continuous infusion with bupivacaine 0.25% or ropivacaine 0.2% is instituted promptly. The infusion rate is titrated for optimal pain relief to a maximal dose of 0.4 mg/kg/hour. The catheters remain in situ for up to 14 days by which time the pain can be managed with oral opioids (Table 1) .
CASE REPORTS
Case number 1
An elementary (primary) school 35 kg child was admitted due to a massive shoulder tumour and excruciating pain. Biopsy showed osteosarcoma involving the left proximal humerus. During the six months prior to admission, the patient received several weeks of chemotherapy with alternating doxorubicin/cisplatin and high-dose methotrexate at another paediatric hospital. The patient was treated successfully for pain with intravenous (IV) patient-controlled analgesia morphine and began oral gabapentin one week before amputation: the initial dose of gabapentin was 100 mg three times per day (tds), and this was increased to 300 mg tds at the time of surgery. Vancomycin was given preoperatively.
The patient underwent left FQA with nerve sheath catheter placement. After a bolus of bupivacaine 0.25% 20 ml, a continuous infusion of bupivacaine 0.25% (6 ml/hour) was commenced in the operating room. gabapentin was increased to 400 mg tds postoperatively. The patient received IV ceftriaxone and vancomycin for four days postoperatively and was then discharged on oral cephalexin. On postoperative day (POD) 1 through to 3, there were no complaints of PLP. On POD 4, the patient reported mild PLP in his hand that was rated as 2 to 4 on a 10-point numeric rating scale (NRS), and gabapentin was increased to 500 mg tds. Two of the three catheters were removed on POD 5 due to leakage from the amputation site. The patient was discharged on ropivacaine 0.2% (4 ml/ hour) in the remaining catheter, oral slow-release morphine (20 mg twice daily), and immediaterelease morphine (10 to 20 mg every four hours as needed). On POD 7, the patient reported pain (4 out of 10 on the NRS) in the missing hand that was worse at night. gabapentin was increased to 600 mg tds. The following day the patient had not required any morphine for breakthrough pain in the previous 24 hours, and the remaining catheter was removed. On POD 12, the patient rated PLP at 2 to 3 out of 10 on the NRS but had been sleeping well and had not taken any immediaterelease morphine for pain in the past two days. Slow-release morphine was decreased to 20 mg once daily. Two and a half weeks after surgery, the patient denied any pain and had used no immediaterelease morphine for four days. Slow-release morphine was discontinued, although gabapentin (600 mg tds) was continued. On POD 26, the gabapentin dose was further decreased to 300 mg twice daily, and on POD 40 it was discontinued. No further PLP was reported. Five months after the FQA, the patient died of lung metastases.
Case number 2
An elementary school, 41 kg child presented with shoulder pain to the family primary care physician. A percutaneous needle biopsy showed a high-grade osteosarcoma of the right proximal humerus. Right FQA was scheduled due to the extensive disease. During the three months preceding the amputation, the patient received chemotherapy with bevacizumab, cisplatin, doxorubicin and high-dose methotrexate. Five days before the FQA, the patient started gabapentin (100 mg tds); this dose was increased to 200 mg tds three days later. Cefuroxime and vancomycin were given IV preoperatively.
During right FQA, three nerve sheath catheters were inserted and bolused with bupivacaine 0.5% 20 ml and an infusion of ropivacaine 0.2% (8 ml/hour) was started. Immediately after surgery, the patient received IV cefuroxime and vancomycin. Postoperatively, the patient complained of right arm PLP and back pain rated at 6 out of 10 on the NRS. On POD 1, the patient had phantom sensations consisting of 'fingers crossing', feelings of 'wanting to make a fist', and burning PLP in the right arm and shoulder rated at 4 out of 10 on the NRS. The patient was treated with IV hydromorphone (1 mg per hour as needed). The gabapentin dose was increased to 300 mg tds. The PLP improved, but phantom sensations persisted. The patient was discharged on POD 4 with oral hydromorphone (2 mg every four hours as needed), gabapentin (400 mg tds) and nerve sheath catheter infusion of ropivacaine 0.2% (8 ml/hour). Two days later, the patient returned to the clinic with PLP rated at 7 out of 10 on the NRS in his 'ghost hand', and was given IV hydromorphone (1mg) with good relief. The gabapentin dose was increased to 600 mg tds. On POD 7, the patient reported more intense and more frequent PLP; thus, oral amitriptyline (20 mg once daily) was started, and the gabapentin dose was increased to 800 mg tds. The patient denied any pain for the next two days, and the brachial plexus catheters were removed on POD 9. The following day, the patient returned to the outpatient clinic with excruciating PLP in his thumb that was relieved by IV methadone (4 mg). Oral methadone (5 mg twice daily) was commenced, and gabapentin was increased to 900 mg tds. Over the next five days, the patient complained of PLP daily, ranging between 4 and 6 out of 10 on the NRS and described it with qualifications such as, "it stings". By POD 16, the patient complained of "constant phantom pain" up to 8 out of 10 on the NRS, which was relieved by IV hydromorphone (1 mg). Oral methadone was increased to 10 mg twice daily. On POD 24, the patient had no further pain, and methadone was decreased to 5 mg twice daily. On POD 40, amitriptyline was discontinued; on POD 43, gabapentin was discontinued; and on POD 71, methadone was discontinued. There were no complaints of PLP for the next 24 months of follow-up.
Case number 3
An elementary school, 45 kg child presented with pain and swelling of the left arm. A needle biopsy revealed a high-grade osteosarcoma of the left proximal humerus. The patient underwent left FQA after four months of chemotherapy with bevacizumab, cisplatin, doxorubicin and highdose methotrexate. Fifteen days prior to surgery, a percutaneous left interscalene catheter was placed, and bupivacaine 0.20% was commenced at 6 ml/hour. gabapentin was started at 300 mg tds and was increased to 600 mg tds a week before surgery. Vancomycin and cefuroxime IV were given preoperatively.
During left FQA, three nerve sheath catheters were inserted under direct vision by the surgeon. After a bolus of bupivacaine 0.25% 20 ml, an infusion of ropivacaine 0.2% was started at 8 ml/hour. The patient denied pain postoperatively and had no morphine use during the next 24 hours. gabapentin was increased to 900 mg tds. The patient experienced excellent pain control with no reports of PLP, and on POD 3, a total of only four doses of IV morphine (2 mg) had been given for mild shoulder pain. The patient was discharged on POD 4 with ropivacaine 0.2% (8 ml/hour), immediate-release morphine (5 to 10 mg every two hours as needed), gabapentin (900 mg tds), and trimethoprim/sulfamethoxazole. On POD 7, the ropivacaine infusion rate was decreased to 7 ml/hour due to leakage at the dressing site. On POD 8, the infusion of ropivacaine was replaced with bupivacaine 0.2% (7 ml/ hour). During the dressing change on POD 10, the middle catheter was found disconnected and was removed. The remaining catheters were removed on POD 14. On POD 16 oral slow-release morphine (15 mg twice daily) was commenced due to several episodes of PLP in the 24 hours prior to the visit. During the following week, the opioids were gradually reduced and discontinued, and the patient had no further complaints of pain. On POD 26, all pain medications were discontinued. There were no complaints of PLP in the 18 months of follow-up.
Case number 4
An elementary school, 56 kg child was transferred to St. Jude Children's Research Hospital with a painful, swollen right arm and radiological evidence of a tumour and pathologic fracture. An open biopsy of the right humerus revealed telangiectatic osteosarcoma. gabapentin was started at 200 mg tds and titrated up to 1200 mg tds. The patient received chemotherapy consisting of cisplatin, bevacizumab, doxorubicin, and highdose methotrexate for four months prior to amputation. A percutaneous right interscalene catheter was inserted and a continuous infusion of ropivacaine 0.2% (8 ml/hour) was commenced. The catheter was in place for 36 days, after which it had to be removed for an MRI scan as it was not MRI compatible. Pain control was subsequently achieved with oral morphine (15 mg every six hours as needed) and gabapentin (1200 mg tds). The patient received vancomycin IV preoperatively and cefepime IV in the recovery room and postoperatively.
Right FQA was performed with intraoperative placement of three nerve sheath catheters. After a bolus of bupivacaine 0.5% 20 ml, an infusion of ropivacaine 0.2% (10 ml/hour) was commenced and continued postoperatively. On the day of the FQA, the patient received IV cefepime which was continued until POD 7. For the next week, the patient's pain was controlled by the nerve sheath catheter infusion, gabapentin (1200 mg tds), morphine (2 to 4 mg per hour as needed, IV), ketorolac (30 mg per eight hours, IV), amitriptyline, and lorazepam (1 mg as needed, IV) for anxiety. During this time, the patient did not complain of PLP. On POD 8, the patient reported PLP in the missing arm described as "sharp tingling pain" and rated as 10 out of 10 on the NRS. Morphine (2 mg, IV) was administered with good pain relief. The patient had no complaints of PLP after this isolated incident. Ropivacaine 0.2% was decreased to 5 ml/hour on POD 11 with good pain control, and the catheters were removed on POD 14. On POD 12, oral methadone (5 mg twice daily) was initiated for neuropathic pain in the lower limbs. The dose was increased to 20 mg tds over the following three weeks. Methadone was then reduced and discontinued after three months. No further PLP was reported. The patient died of progressive lung metastases one year after FQA.
DISCUSSION
We present four paediatric patients who underwent FQA for attempted curative treatment of osteosarcoma. In all cases, preoperative pain was present, and preoperative chemotherapy was administered. Nerve sheath catheters were placed in the brachial plexus intraoperatively and left in situ for 5 to 14 days. Three of the four children experienced successful pain management with the catheters as outpatients. All four patients experienced PLP; however, with multimodal analgesia, it did not persist beyond four weeks in any patient.
The most recent studies of this procedure, published 15 years ago, indicate that as many as 92% of paediatric patients experience PLP after amputation 7 . All of the patients in our case series were at higher than baseline risk due to multiple risk factors including preoperative pain 7 , the indication for amputation (i.e., cancer) 6 , the proximal and upper limb location of the amputation 5,9-11 and the administration of pre-amputation chemotherapy 6, 9 . Several studies have shown that continuous peripheral nerve block reduces the opioid dosage necessary to effectively control postoperative pain [12] [13] [14] . However, the efficacy of perineural catheters for preventing PLP remains controversial.
Some studies have found no significant reduction in PLP 4, 12, 15 , while other case reports and studies have shown a significant reduction in postoperative pain and PLP 5, 13, 14, 16, 17 . Wittig et al reported that eight adult patients who received perineural catheters after palliative FQA had no PLP 3 . All of the patients in our study received gabapentin prior to amputation. Chemotherapy-induced neuropathy can have an additive effect on neuronal injury caused by surgical procedures. However, gabapentin may decrease that risk, as it has been shown to reverse the effects of chemotherapyinduced neuropathy in an animal model 18 . Findings from clinical trials of gabapentin and PLP have been conflicting. Some studies have reported that gabapentin is an effective treatment for established PLP 19 . However, other studies did not show positive results of pre-emptive gabapentin use or successful treatment of established PLP 20, 21 . In some patients following amputation, adequate analgesia of PLP is difficult to achieve. In our institution, when patients continue to suffer PLP after gabapentin has been titrated to the maximal dose and amitriptyline has been added, methadone is generally considered. Because of its long and variable half-life, methadone is not our first choice for PLP; however, it may be useful when all other neuropathic pain medications have failed 22 . Although technical complications such as catheter disconnection are the most common problems with perineural catheters, the more serious concern is infection, especially in immunologically compromised patients 23 . The rate of catheter colonisation varies depending on the site of placement and whether subcutaneous tunnelling is used. It may be as low as 6% or as high as 57% 24, 25 . The rate of clinically relevant infection is much lower, with one series of more than 400 tunnelled catheters resulting in no clinically significant infections 24 . However, all of these studies included patients with catheters in place for only two to four days; our patients had them in situ for five to 14 days. Although there have been several case reports of much longer catheter placement 3, 26 , no data are available on the risk of infection for this offlabel usage. Most studies indicate that increasing the duration of catheter usage places the patient at greater risk of infection 23 . All four of our patients were given a cephalosporin (ceftriaxone, cefepime, or cefuroxime) and vancomycin on the day of the surgery and continued IV antibiotics while they were inpatients; one patient continued cephalexin as an outpatient.
We acknowledge that a limitation of this case series is that of a variable approach in the selection of the local anaesthetic solutions for bolus doses and infusions. The selection of local anaesthetic solutions for the bolus dose and the postoperative infusions is left to the choice of the anaesthetist. Preference is usually given to a bupivacaine bolus, either 0.25% or 0.5%, in order to establish an initial dense block. For the subsequent infusion, we tend to favour a ropivacaine infusion based on the lower risk of cardiac toxicity than that associated with bupivacaine. Infusion rates for bupivacaine or ropivacaine are not to exceed 0.4 mg/kg/hour, according to the St. Jude Children's Research Hospital institutional policy. Adequate analgesia was obtained in all cases and analgesic efficacy was not influenced by the selection of local anaesthetic in our series.
Our current institutional practice for minimising PLP is multimodal: nonpharmacological and pharmacological. Pharmacological approaches rely on nerve block infusions and systemic medication. While opioids are our standard of therapy for nociceptive pain, the neuropathic pain (PLP included) algorithm is based on escalating regimens of anticonvulsants (gabapentin), best instituted before the amputation, tricyclic antidepressants (amitriptyline) and methadone.
CONCLUSION
In conclusion, nerve sheath catheters placed intraoperatively during FQA may be useful in conjunction with multimodal analgesia for the management of postoperative PLP in paediatric oncology patients. In our series, four patients had brachial plexus catheters in place for up to 14 days, and pain was managed successfully in three as outpatients. All patients received perioperative antibiotics, and none experienced a catheterrelated infection. No patient in this high-risk group experienced persistent PLP beyond one month. Although we have demonstrated the feasibility and efficacy of this technique, further prospective studies are required to establish the role of regional anaesthesia in the prevention of PLP. The Journal was recently contacted by a reader who pointed out similarities between a paper published in our journal 1 and another by different authors published previously elsewhere 2 . On examination of the papers in question, it became apparent that there are indeed varying degrees of textual overlap in all sections of the later paper. An explanation was requested from the corresponding author, along with evidence for the veracity of the data. A prompt response was received, which included material providing what is believed to represent adequate confirmation of the study itself. The authors acknowledge that their paper had been rejected by two other journals prior to submission to Anaesthesia and Intensive Care, that difficulty with English had been a significant factor in those rejections, and that in an effort to make the English more acceptable in the revised version submitted to Anaesthesia and Intensive Care they had modelled the text too closely on that of the previous publication, which had also been the stimulus for the conduct of their own study. The authors apologise to those of the previous paper, to the journals concerned and to their readers.
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